


What is claimed is:

1. A combination which comprises (a) a vasculostatic compound and (b) an alkylating agent in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt for simultaneous, separate or sequential use.
2. A combination according to claim 1 wherein the alkylating agent is selected from the group consisting of alkyl sulfonates, aziridines, epoxides, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, imidazotetrazinones, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman and procarbazine.
3. A combination according to claim 1 or 2 wherein the vasculostatic compound is a compound of formula I



wherein

r is 0 to 2,

n is 0 to 2,

m is 0 to 4,

R<sub>1</sub> and R<sub>2</sub> (i) are lower alkyl or

(ii) together form a bridge in subformula I\*



the binding being achieved via the two terminal carbon atoms, or

(iii) together form a bridge in subformula I\*\*



wherein one or two of the ring members T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub> and T<sub>4</sub> are nitrogen, and the others are

in each case CH, and the binding is achieved via T<sub>1</sub> and T<sub>4</sub>;

A, B, D, and E are, independently of one another, N or CH, with the stipulation that not more than 2 of these radicals are N;

G is lower alkylene, lower alkylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, oxa (-O-), thia (-S-), or imino (-NH-);

Q is lower alkyl;

R is H or lower alkyl;

X is imino, oxa, or thia;

Y is unsubstituted or substituted aryl, pyridyl, or unsubstituted or substituted cycloalkyl; and

Z is amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower alkylthio, alkylphenylthio, phenylsulfonyl, phenyl-lower alkylsulfinyl or alkylphenylsulfinyl, substituents Z being the same or different from one another if more than 1 radical Z is present;

and wherein the bonds characterized, if present, by a wavy line are either single or double bonds;

or an N-oxide of the defined compound, wherein 1 or more N atoms carry an oxygen atom, or the salt of such compound having at least one salt-forming group.

4. A combination according to claim 1 wherein the vasculostatic compound is PTK787 or a salt thereof and the alkylating agent is temozolomide or lomustine.
5. A combination according to any one of claims 1 to 4 for use in the treatment of a tumor disease.
6. Use of a combination according to any one of claims 1 to 4 for the preparation of a medicament for use in the treatment of a tumor disease.
7. A method of treating a warm-blooded animal having a tumor disease which comprises administering to the animal a combination according to any one of claims 1 to 4 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

8. A method of inhibiting the formation of metastases in a warm-blooded animal having a tumor disease which comprises administering to the patient a pharmaceutically effective amount of a combination according to any one of claims 1 to 4 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
9. A method according to claim 7 wherein the tumor disease is glioblastoma.
10. A method according to any one of claims 7 wherein the vasculostatic compound is PTK787 or a salt thereof.
11. A method according to any one of claim 10 wherein PTK787 is administered in a daily dose between 250 and 2000 mg.
12. A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a tumor disease of a pharmaceutical combination according to any one of claims 1 to 4 and at least one pharmaceutically acceptable carrier.
13. A commercial package comprising a combination according to any one of claims 1 to 4 together with instructions for simultaneous, separate or sequential use thereof in the treatment of a tumor disease.